Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 8/2006

01-08-2006 | Current Opinion

Overuse of Antidepressant Drugs for the Treatment of Depression

Authors: Dr Jon Jureidini, Anne Tonkin

Published in: CNS Drugs | Issue 8/2006

Login to get access

Abstract

The problem of under-diagnosis and under-treatment of depression has been identified as a major public health issue and measures have been taken to increase the recognition of depression and its treatment with antidepressants. The possibility of harm from the overuse of antidepressants has attracted far less attention. This review sets out evidence to show that inappropriate use of antidepressants (i.e. outside clinical indications, in excessive doses and for prolonged periods) constitutes a concerning public health problem. Antidepressant prescribing increased by between 4- and 10-fold in various age groups and countries in the last decade of the 20th century. The population of severely depressed patients (in whom antidepressants are accepted to be an effective treatment) who are not receiving antidepressants is probably much smaller than the population receiving these drugs inappropriately. We sound a note of caution for depression awareness campaigns. These apparently well-reasoned responses to the perceived under-recognition of depression can exacerbate over-prescribing. Unless prescribing patterns change, any benefits from increasing access to antidepressants for those with severe depression will be accompanied by significant harms due to inappropriate prescribing in conditions, such as mild depression, where antidepressants are not indicated
Literature
1.
2.
3.
Geddes JR, Freemantle N, Mason J, et al. Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression. Cochrane Database Syst Rev 1999; (4): CD001851
4.
National Collaborating Centre for Mental Health. Depression: management of depression in primary and secondary care. London: National Institute for Clinical Excellence, 2004
5.
Goff VV. Depression: a decade of progress, more to do. NHPF Issue Brief 2002 Nov 22; (786): 1–14PubMed
6.
Zito JM, Safer DJ, dosReis S, et al. Psychotropic practice patterns for youth; a ten year perspective. Arch Pediatr Adolesc Med 2003; 157: 17–25PubMedCrossRef
7.
Hall WD, Mant A, Mitchell PB, et al. Association between antidepressant prescribing and suicide in Australia, 1991–2000: trend analysis. BMJ 2003; 326: 1008–12PubMedCrossRef
8.
Ciuna A, Andretta M, Corbari L, et al. Are we going to increase the use of antidepressants up to that of benzodiazepines? Eur J Clin Pharmacol 2004; 60: 629–34PubMedCrossRef
9.
Shatin D, Drinkard CR. Ambulatory use of psychotropics by employer-insured children and adolescents in a national managed care organization. Ambul Pediatr 2002; 2: 111–9PubMedCrossRef
10.
Rosholm J-U, Gram LF, Isacsson G, et al. Changes in the patter of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Eur J Clin Pharmacol 1997; 52: 205–9PubMedCrossRef
11.
Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001; 3: 22–7PubMedCrossRef
12.
13.
Fergusson D, Doucette S, Cranley Glass K, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330: 396–402PubMedCrossRef
14.
Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 2005; 330(7488): 385–8PubMedCrossRef
15.
Olfson M, Shaffer D, Marcus S, et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry 2003; 60: 978–82PubMed
16.
Gibbons R, Hur K, Bhaumik D, et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62: 165–72PubMedCrossRef
17.
De Leo D, Evans R. International suicide rates and prevention strategies. Washington, DC: Hogrefe & Huber, 2004
18.
Delate T, Gelenberg AJ, Simmons VA, et al. Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998–2002. Psychatr Serv 2004; 55: 387–91CrossRef
19.
Sparks JA, Duncan BL. The ethics and science of medicating children. Ethical Hum Psychol Psychiatry 2004; 6: 25–39PubMed
20.
De Las Cuevas C, Sanz EJ, De La Fuente JA. Variations in antidepressant prescribing practice: clinical need or market influences? Pharmacoepidemiol Drug Saf 2002; 11: 515–22PubMedCrossRef
21.
Donohue JM, Berndt ER, Rosenthal M, et al. Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression. Med Care 2004; 42: 1176–85PubMedCrossRef
22.
Licht R, Qvitzau S, Allerup P, et al. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity? Acta Psychiatr Scand 2005; 111: 144–9PubMedCrossRef
23.
Ellis P, Smith D. Treating depression: the beyondblue guidelines for treating depression in primary care. “Not so much what you do but that you keep doing it”. Med J Aust 2002; 176: S77–83PubMed
24.
25.
26.
Martinez C, Rietbrock S, Wise L, et al. Anti-depressant treatment on the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005; 330: 389–95PubMedCrossRef
27.
Elkin I, Gibbons RD, Shea MT, et al. Initial severity and differential treatment outcome in the National Institute of Mental Health treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1995; 63: 841–7PubMedCrossRef
28.
Barrett JE, Williams JR JW, Oxman TE, et al. Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18–59 years. J Fam Pract 2001; 50: 405–12PubMed
29.
Mant A, Rendle V, Hall W, et al. Making new choices about antidepressants in Australia: the long view 1975–2002. Med J Aust 2004; 181: S21–4PubMed
30.
Rushton JL, Clark SJ, Freed GL. Pediatrician and family physician prescription of selective serotonin reuptake inhibitors. Pediatrics 2000; 105: 82–7CrossRef
31.
Harrison C, Britt H. The rates and management of psychological problems in Australian general practice. Aust N Z J Psychiatry 2004; 38: 781–8PubMedCrossRef
32.
Andrews G, Carter GL. What people say about their general practitioners’ treatment of anxiety and depression. Med J Aust 2001; 175: S48–51PubMed
33.
Drug Utilisation Sub-Committee. Australian statistics on medicines 2001–2002. Canberra (ACT): Australian Government, Department of Health and Ageing, 2004
34.
Hollinghurst S, Kessler D, Peters T, et al. Opportunity cost of anti-depressant prescribing in England: analysis of routine data. BMJ 2005; 330: 989–1000CrossRef
35.
Andrews G, Sanderson K, Corry J, et al. Using epidemiological data to model efficiency in reducing the burden of depression. J Ment Health Policy Econ 2000; 3: 175–86PubMedCrossRef
36.
Katz SJ, Kessler RC, Lin E, et al. Medication management of depression in the United States and Ontario. J Gen Intern Med 1998; 13: 77–85PubMedCrossRef
37.
Alonso J, Angermeyer MC, Bernert S, et al. Psychotropic drug utilization in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; 420: 55–64PubMed
38.
Pomerantz JM, Finkelstein SN, Berndt ER, et al. Prescriber intent, off-label usage, and early discontinuation of antidepressants: a retrospective physician survey and data analysis. J Clin Psychiatry 2004; 65: 395–404PubMedCrossRef
39.
Moynihan R, Cassels A. Selling sickness: how drug companies are turning us all into patients. Sydney: Allen & Unwin, 2005
40.
Reed E, Vance A, Luk E, et al. Single and combined psychotropic medication use in a child and adolescent mental health service. Aust N Z J Psychiatry 2004; 38: 204–11PubMedCrossRef
41.
Kapczinski F, Lima MS, Souza JS, et al. Antidepressants for generalized anxiety disorder (review). Cochrane Database Syst Rev 2003; (2): CD003592PubMed
42.
Algulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder; twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179: 15–22CrossRef
43.
Linjakumpu T, Hartikainen S, Klaukka T, et al. Psychotropics among the home-dwelling elderly: increasing trends. Int J Geriatr Psychiatry 2002; 17: 874–83PubMedCrossRef
44.
Mamdani M, Rapoport M, Shulman Kl, et al. Mental health-related drug utilization among older adults; prevalence, trends and costs. Am J Geratr Psychiatry 2005; 13: 892–900
45.
Spore DL, Mor V, Larrat P, et al. Regulatory environment and psychotropic use in board-and-care facilities: results of a 10-state study. J Gerontol A Biol Sci Med Sci 1996; 51: M131–41PubMedCrossRef
46.
Furniss L, Burns A, Craig SKL, et al. Effects of a pharmacist’s medication review in nursing homes: randomised controlled trial. Br J Psychiatry 2000; 176: 563–7PubMedCrossRef
47.
Chu L, Schnelle JF, Osterweil D. Prescription analgesic and antidepressant utilization and cost among elderly Medicaid beneficiaries before and after nursing home admission. J Am Med Dir Assoc 2004; 5: 75–81PubMedCrossRef
48.
Snowdon J, Burgess E, Vaughan R, et al. Use of antidepressants, and the prevalence of depression and cognitive impairment in Sydney nursing homes. Int J Geratric Psychiatry 1996; 11: 599–606CrossRef
49.
Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc 2001; 49: 200–9PubMedCrossRef
50.
Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132: 743–56PubMed
51.
Burrows AB, Salzman C, Satlin A, et al. A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depression. Depress Anxiety 2002; 15: 102–10PubMedCrossRef
52.
Bourin M. Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review. Hum Psychopharma-col 2003; 18: 185–90CrossRef
53.
Jureidini J, Doecke C, Mansfield P, et al. Efficacy and safety of antidepressants for children and adolescents. BMJ 2004; 328: 879–83PubMedCrossRef
54.
Brent D. Antidepressants and pediatric depression: the risk of doing nothing. N Engl J Med 2004; 351: 1598–601PubMedCrossRef
55.
Tonkin A, Jureidini J. Wishful thinking: antidepressant drugs in childhood depression. Br J Psychiatry 2005; 187: 304–5PubMedCrossRef
56.
Lyons JS, MacIntyre JC, Lee ME, et al. Psychotropic medications prescribing patterns for children and adolescents in New York’s public mental health system. Community Ment Health J 2004; 40: 101–18PubMedCrossRef
57.
National Collaborating Centre for Mental Health. Schizophrenia: full national clinical guideline on core interventions in primary and secondary care. London: Gaskell and British Psychological Society, 2003
58.
Gilberg K, Laouri S, Wade S, et al. Analysis of medication use patterns: apparent overuse of antibiotics and underuse of prescription drugs for asthma, depression and CHF. J Managed Care Pharm 2003; 3: 232–7
59.
Tierney R, Melfi CA, Signa W, et al. Antidepressant use and use patterns in naturalistic settings. Drug Benefit Trends 2000; 6: 7–12
60.
Healy D, Aldred G. Anti-depressant drug use and the risk of suicide. Int Rev Psychiatry 2005; 17: 163–72PubMedCrossRef
61.
Kessler R, Berglund P, Dernier O, et al. The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R). JAMA 2003; 289: 3095–105PubMedCrossRef
62.
Spijker J, deGraaf R, Bijl R, et al. Duration of major depressive episodes in the general population: results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). Br J Psychiatry 2002; 181: 208–13PubMedCrossRef
63.
Thomson O’Brien MA, Oxman AD, Davis DA, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2000; (2): CD000409
Metadata
Title
Overuse of Antidepressant Drugs for the Treatment of Depression
Authors
Dr Jon Jureidini
Anne Tonkin
Publication date
01-08-2006
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 8/2006
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200620080-00002

Other articles of this Issue 8/2006

CNS Drugs 8/2006 Go to the issue

Therapy In Practice

Management of Psychiatric Comorbidity in Anorexia Nervosa and Bulimia Nervosa

Adis Drug Profiles

Galantamine Extended Release

Adis Drug Profiles

Pregabalin in the Treatment of Generalised Anxiety Disorder

Current Opinion

Current Issues in the Treatment of Acute Posterior Circulation Stroke

Adis Drug Profiles

Galantamine Extended Release

Adis Drug Profile

Galantamine Extended Release